 |
 |
Get in Now in this Exciting New Deal from SmallCapVoice.com
Medifocus, Inc.
The Exchange Tower, PO Box 427
130 King Street West, Suite 1800
Toronto, Ontario MSX 1 E3
905-319-7070
prolieve.com
medifocusinc.com
Profile:
Medifocus Incorporated (TSX-V: MFS and OTC-QX: MDFZF) is a public company listed in the USA and Canada. Medifocus is a high technology medical system and device company. The Company has developed two therapeutic products, Prolieve, for the treatment of BPH (Benign Prostatic Hyperplasia), and the APA-1000, for treatment of Breast Cancer. Prolieve is a FDA approved commercial product and is producing revenue. The APA-1000 is in advanced stage of clinical development and has received both the FDA and Health Canada approval to enter the final pivotal phase-III clinical trial, which is the final step before commercial approval.
Medifocus has two technology platforms for development of future products. They are the "Prolieve Endo-thermotherapy Platform" and the "Adaptive Phased Array Microwave Focusing Platform". Comprehensive portfolios of US & International patents protect both platforms. The development of Prolieve was based on endo-thermotherapy and the APA-1000 is an Adaptive Phased Array System.
Prolieve can be marketed to the 8.0 Billion Dollar BPH Drug Therapy Market
Medifocus has already raised a total of over 9.1 million dollars equity funding to finance the Prolieve purchase and grow its business based on cash flow and profit generated from Prolieve sales.
The Prolieve thermo-dilatation treatment is a 45 minutes minimally invasive procedure performed in a physician's office. After treatment, the patient resumes normal activities, experiences significant BPH symptoms relief and quality of life improvements. 99% of the patients treated do not experience any effect in sexual function.
The APA 1000 System for Breast Cancer treatment
The APA 1000 is a Breast Cancer Treatment System developed based on the Adaptive Phased Array technology platform licensed from the Massachusetts Institute of Technology (MIT). A comprehensive portfolio of 44 US and 35 International patents protects the APA Technology Platform. Medifocus has taken the product from animal studies through phase I and phase II clinical trials and has received approval from both the FDA and Health Canada to begin the pivotal phase III clinical trial, which is the last step before receipt of the PMA for commercialization. The APA 1000 can be used to treat all types and forms of breast cancer ranging from treatment of DCIS, shrink small, medium and large breast tumors to improve surgical outcomes and for treatment of Recurrent Chest Wall cancers (RCW). The first indication for treatment of medium sized breast tumors has a total addressable marketplace of 4 billion dollars.
Investment Highlights:
 |
- Medifocus is a medical device company with a revenue producing FDA approved product for treatment of BPH and is in Phase III trial for its second product for treatment of breast cancer.
- Virtually no debt, growing revenue with an undervalued market cap.
- Prolieve presents excellent revenue growth, high gross margins and contribution to overhead to fund the APA 1000 Phase III clinical trial to completion and product commercialization.
- Both Prolieve and the APA 1000 can be marketed worldwide.
- Patented technology platforms for development of other disease targeted heat treatment systems and devices.
- The APA system has already received the pre-market approval (PMA) from the FDA as an adjunct to radiation for treatment of surface and subsurface cancers.
- The Company is ready to enter into the Pivotal clinical trial for obtaining another PMA for the system to treat breast cancer. Prior clinical results have already demonstrated that combined heat and neo-adjuvant chemotherapy improves breast tumor shrinkage by an additional 50% over neo-adjuvant chemotherapy alone.
- Globally, over 1.2 million new cases of breast cancer are reported each year, and over 450,000 new cases a year are expected by 2017 in Canada and the USA. The management has substantial industry experience in commercialization of heat treatment devices and systems.
Medifocus 5-year Revenue and Cash Flow Projection
- A minimum investment of 9 million dollars is needed to sustain the strategy and the amount has already been raised.
- Medifocus is self sufficient for its first full year after receipt of the 9.1 million dollar investment, i.e. complete the payment of the balance of 2.5 million dollars due BSX in 3 years, manage the phase III trial to completion and receive the FDA approval, become cash flow positive and generate a profit of 0.98 million dollars in its second year.
- Prolieve Sales is projected to grow from 6.5 million dollars in year-1 to 43 million dollars in year-5.
- Company's profit is projected to grow from 983K dollars in yr-2 to 16.5 million dollars in yr-5.
A Recent Trade Alert From Stock Legend Stated:
With only 74 million shares in the OS, and 24 million as of April 30 in the float the share structure is priced to move by all standards of the market!
With an opportunity to grab shares at its current price of 0.11 any potential catalysts could send the stock into orbit! As an investor your profits could fly like an Eagle carrying a Golden egg! The Stock Legends Team feels as if there is a significant opportunity for investors in MDFZF! The Due Diligence on the company is solid and there is plenty on the horizon for the investors and company in the race against cancer! Get ready to come out swinging tomorrow at the Bell with ticker MDFZF! |
|
TSX-V: MFS
OTC: MDFZF
Price as of 10/3/12:
0.145
52 Week Range:
0.35 - .001
Authorized Shares:
Limited to TSX-V approval
Outstanding Shares as of l0/2112:
96,949,228
Float as of 4/30/11:
24,337,335
Est. Market Cap:
14M
Avg. Volume (3 mo.):
9,422
Transfer Agent:
Equity Transfer & Trust Company
RECENT NEWS:
Medifocus Inc. to Attend Two Upcoming Regional American Urological Association (AUA) Meetings to Promote the Prolieve(R) Device System
Medifocus Inc. Announces Update on the Prolieve(R) Acquisition and the Hiring of the Prolieve(R) Management Team
KEY EXECUTIVES:
Dr. Augustine Y. Cheung, PhD
President and CEO
Mr. John Mon
COO
Mr. Mirsad Jakubovic
CFO
Mr. Dennis Smith
VP, Engineering
|
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
